Phase II study of Bendamustine-Rituximab therapy for CD20-positive untreated and advanced follicular lymphoma with poor response to R-CHOP therapy - Bendamustine Convert Study

Department of Hematology and Rheumatology,Kinki University Faculty of Medicine0 个研究点目标入组 60 人开始时间: 2014年4月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Any other active malignancies 2)Uncontrollable serious complications (diabetes, heart failure, cardiomyopathy, abnormal heart rhythm, angina, myocardial infarction, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, infection, a respiratory failure, an organic lung disease, hepatic insufficiency, liver cirrhosis, acute chronic hepatitis, renal insufficiency, etc.) patients with active tuberculosis 3)Circulating lymphoma cells >= 25,000 /uL in peripheral blood 4)Primary central nervous system lymphoma or central nervous system invasion 5)Anaphylactic shock for any drugs 6)The HCV antibody-positive 7)Inappropriate for rituximab treatment 8)Serious mental disorder, such as schizophrenia 9)Diagnosed as a malignant lymphoma, leukemia, and myelodysplastic syndromes in the past 10)The treatment history of the chemotherapy, the radiotherapy, cytokine therapy, and antibody therapy to FL 11)Pregnant/female patients who are unwilling to take prevention measures for contraception during treatment 12)HIV antibody-positive 13)Inappropriate for entry by physician's decision

发起方

Department of Hematology and Rheumatology,Kinki University Faculty of Medicine